Singapore markets open in 2 hours 28 minutes

ASLAN Pharmaceuticals Limited (ASLN)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.4690+0.0140 (+3.08%)
At close: 04:00PM EDT
0.4678 -0.00 (-0.26%)
After hours: 06:19PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.4550
Open0.4470
Bid0.4560 x 100
Ask0.0000 x 0
Day's range0.4450 - 0.5200
52-week range0.3920 - 4.6900
Volume1,494,565
Avg. volume1,183,783
Market cap10.612M
Beta (5Y monthly)1.47
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

    Interim readout of 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab-experienced AD patients treated with 400mg eblasakimab weekly achieved EASI-90 (at least a 90% reduction in their Eczema Area Severity Index (EASI) score) and 66.7% achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks, versus 14.3% of patients on placebo. 20% of patients treated with eblasakimab achieved EASI-100 (100% reducti

  • GlobeNewswire

    ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice

    SAN MATEO, Calif. and SINGAPORE, April 19, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it received a letter (the “Letter”) on April 18, 2024 from The Nasdaq Stock Market (“Nasdaq”) informing the Company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Mark

  • GlobeNewswire

    ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

    In a preliminary review of blinded data from the ongoing TREK-DX study, 45% (10/22) of patients achieved at least a 90% reduction in their EASI score (EASI-90) after 16 weeks. 56% (5/9) of patients with prior inadequate response to dupilumab achieved EASI-90 and 56% (5/9) of patients achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks. Topline, unblinded data from the full dataset expected at the end of 2024.Phase 2 proof-of-concept trial of farudodstat in alopecia areata